We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SSc-ILD

News List

DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung diseas expresspharma
May 21, 2020
Approval is based on the SENSCIS study which showed Nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD).
Boehringer Ingelheim gets EC approval for nintedanib to treat SSc-ILD pharmaceutical-business-review
April 26, 2020
Boehringer Ingelheim has secured approval from the European Commission (EC) for its nintedanib to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adult patients.
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD) drugs
September 09, 2019
The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated...